Fingolimod (Gilenya, Tascenso ODT)
Fingolimod (Gilenya, Tascenso ODT) is a once daily, oral medication for the treatment of relapsing forms of MS. Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod phosphate. Fingolimod phosphate is a sphingosine 1-phosphate receptor modulator that binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which fingolimod exerts therapeutic effects in MS is unknown, but may involve reduction of lymphocyte migration into the CNS.
Additional Information
- National MS Society Gilenya
- National MS Society Tascenso ODT
- VA Fingolimod (Gilenya) Criteria for Use (VA access only)
- VA Fingolimod (Gilenya) Drug Monograph (VA access only)
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.
